Therapeutics Development Core (Core B)
Therapeutics Development Core (Core B)
批准号:
9753229
负责人:
Xunrong Luo
金额:
$26.13万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Animal ModelBiologicalBiological SciencesBlood VesselsCellsChemicalsChemistryChronic Kidney FailureClinicalClinical TrialsCollaborationsConsultationsDevelopmentDevelopmental ProcessDevelopmental Therapeutics ProgramDiabetes MellitusDiabetic NephropathyDiseaseDoctor of PhilosophyDrug KineticsDrug TargetingEnd stage renal failureFeedbackFundingFutureGoalsHematologyHematopoieticHumanIn VitroIncomeInfrastructureInstitutesInterceptInternationalIslets of LangerhansKidneyKidney DiseasesLicensingLifeMedical DeviceMentorsModalityMolecularNanotechnologyNeurologicOrganPathogenesisPharmaceutical PreparationsPhenotypePre-Clinical ModelPreventionProcessProductionQuality ControlRecombinant ProteinsRenal functionReplacement TherapyResearch PersonnelRiskRouteServicesStem cellsSupportive careSystemTestingTherapeuticTissuesToxicologyTranslatingTranslationsTransplantationTreatment EfficacyUniversitiesValidationbaseclinical careclinical translationcommercializationdesigndrug discoveryexperiencehigh throughput screeningimmunoregulationin vivoin vivo imagingin vivo monitoringinnovationkidney repairnanomedicinenovelnovel therapeuticsproduct developmentprogramsregenerative therapyrestorationscale upscreeningsmall moleculesmall molecule therapeuticssynergismtargeted treatmenttechnology developmenttherapeutic developmenttherapeutic targettoolvirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY TO THERAPEUTICS DEVELOPMENT CORE
The goal of the Therapeutics Development Core (Core B) is to establish an efficient platform for
supporting the development and validation of a pipeline of chemical, biological, and cellular
therapeutics for the treatment of a wide spectrum of kidney diseases. Northwestern University (NU) has
been at the forefront of drug discovery for a wide range of diseases, and state-of-the-art infrastructures have
been built that collectively have significantly expanded our therapeutics armamentarium for many diseases
including hematological, oncological, neurological, and rheumatological conditions. However, they have not
been prioritized and tailored to kidney-specific therapeutics development. We propose to fill this gap by
establishing a Therapeutics Development Core within the NU-GoKIDNEY Center. The Therapeutics
Development Core will function as an efficient translational conduit between the Preclinical Models Core (Core
A) and the Clinical and Translational Core (Core C). This Core proposes to provide a “one-stop” shop for
concierge services for access and expert guidance to kidney therapeutics development, with the ultimate goal
of clinical translation. It will be constructed to provide centralized consultation services for developing novel
kidney disease-specific therapeutics to the NU-GoKIDNEY Center investigators for: (1) designing and testing
experimental biological and small molecule therapeutics; (2) designing and testing cellular therapeutics; and
(3) designing and testing nanotechnology-based precision targeting of therapeutic “payloads” to the desired
cells and tissues. Core B will implement a Ph.D.-level Navigator system for maximizing service efficiency and
promoting innovative collaborations. Core B will also use the soon-to-be-launched nephro-HUB to expand the
core user base, track core services, enhance user interactions and promote user collaborations. Core B
Directors and Navigators collectively possess extensive expertise encompassing novel cellular therapeutics
development, virtual drug and biologics design, high-throughput screening platforms for efficiency
determination, and nanotechnology-based precision drug targeting. Core B will formalize and capture this
collective expertise under one roof, and provide investigators of the NU-GoKIDNEY Center with superior
customer service combined with expert guidance in choosing the most efficient route for novel therapeutics
development. By providing these core services, we anticipate that the Therapeutics Development Core will: (1)
accelerate kidney therapeutics development by providing target-specific consultations and navigation through
the processes of therapeutics design, development, validation and production; (2) elevate kidney disease-
specific therapeutics development to the forefront of existing cutting-edge expertise and state-of-the-art
infrastructures in therapeutics development at Northwestern; (3) catalyze and synergize innovative
collaborations within a dynamic network of NU-GoKIDNEY Center investigators via a common platform
provided by the Therapeutics Development Core.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Donor Kidney Resident Macrophages in Kidney Allograft Early Inflammation and Alloimmunity
-
批准号:10467170
-
项目类别:
-
资助金额:$48.47万
-
财政年份:2022
-
负责人:Xunrong Luo
-
依托单位:
Donor Kidney Resident Macrophages in Kidney Allograft Early Inflammation and Alloimmunity
-
批准号:10588212
-
项目类别:
-
资助金额:$48.47万
-
财政年份:2022
-
负责人:Xunrong Luo
-
依托单位:
Therapeutics Development Core (Core B)
-
批准号:10203939
-
项目类别:
-
资助金额:$24.16万
-
财政年份:2018
-
负责人:Xunrong Luo
-
依托单位:
Therapeutics Development Core (Core B)
-
批准号:10460933
-
项目类别:
-
资助金额:$23.0万
-
财政年份:2018
-
负责人:Xunrong Luo
-
依托单位:
Determinants of donor-specific T cell tolerance in kidney transplantation in non-sensitized recipients
-
批准号:10622059
-
项目类别:
-
资助金额:$109.12万
-
财政年份:2017
-
负责人:Xunrong Luo
-
依托单位:
Modeling concurrent cytomegalovirus infection and transplantation tolerance
-
批准号:9240574
-
项目类别:
-
资助金额:$27.04万
-
财政年份:2016
-
负责人:Xunrong Luo
-
依托单位:
Modeling concurrent cytomegalovirus infection and transplantation tolerance
-
批准号:9028961
-
项目类别:
-
资助金额:$27.04万
-
财政年份:2016
-
负责人:Xunrong Luo
-
依托单位:
Protein-Releasing Microporous Scaffolds for Cell Replacement Therapy
-
批准号:9302428
-
项目类别:
-
资助金额:$52.3万
-
财政年份:2010
-
负责人:Xunrong Luo
-
依托单位:
Protein-Releasing Microporous Scaffolds for Cell Replacement Therapy
-
批准号:8886518
-
项目类别:
-
资助金额:$55.87万
-
财政年份:2010
-
负责人:Xunrong Luo
-
依托单位:
ECDI Coupled Cells for Tolerance in Allogeniec Islet Cell Transplantation for T1D
-
批准号:8001130
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2010
-
负责人:Xunrong Luo
-
依托单位:
Clinical Islet Transplantation at Northwestern
-
批准号:7941899
-
项目类别:
-
资助金额:$127.46万
-
财政年份:2009
-
负责人:Xunrong Luo
-
依托单位:
Clinical Islet Transplantation at Northwestern
-
批准号:8117131
-
项目类别:
-
资助金额:$53.38万
-
财政年份:2009
-
负责人:Xunrong Luo
-
依托单位:
ECDI Coupled Cells for Tolerance in Allogeniec Islet Cell Transplantation for T1D
-
批准号:8139432
-
项目类别:
-
资助金额:$0.23万
-
财政年份:2008
-
负责人:Xunrong Luo
-
依托单位:
TGF-beta1 Induced Islet Antigen-Specific Tolerance in Type 1 Diabetes
-
批准号:7679479
-
项目类别:
-
资助金额:$12.72万
-
财政年份:2006
-
负责人:Xunrong Luo
-
依托单位:
TGF-beta1 Induced Islet Antigen-Specific Tolerance in Type 1 Diabetes
-
批准号:7482341
-
项目类别:
-
资助金额:$12.83万
-
财政年份:2006
-
负责人:Xunrong Luo
-
依托单位:
TGF-beta1 Induced Islet Antigen-Specific Tolerance in Type 1 Diabetes
-
批准号:7920864
-
项目类别:
-
资助金额:$9.19万
-
财政年份:2006
-
负责人:Xunrong Luo
-
依托单位:
TGF-beta1 Induced Islet Antigen-Specific Tolerance in Type 1 Diabetes
-
批准号:7147386
-
项目类别:
-
资助金额:$12.72万
-
财政年份:2006
-
负责人:Xunrong Luo
-
依托单位:
TGF-beta1 Induced Islet Antigen-Specific Tolerance in Type 1 Diabetes
-
批准号:7288214
-
项目类别:
-
资助金额:$12.72万
-
财政年份:2006
-
负责人:Xunrong Luo
-
依托单位:
MCMV infection, latency and reactivation in transplantation tolerance
-
批准号:8934957
-
项目类别:
-
资助金额:$37.77万
-
财政年份:--
-
负责人:Xunrong Luo
-
依托单位:
海外基金